Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C4GN
|
|||
| Drug Name |
CD33-CAR-T Cell
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [1] | |
| Haematopoietic/lymphoid cancer [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 1 | [1] | ||
| Company |
M.D. Anderson Cancer Center
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myeloid cell surface antigen CD33 (CD33) | Target Info | CAR-T-Cell-Therapy | [1] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03126864) Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.